Is it safe to use Flexeril (cyclobenzaprine) during the first trimester of pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Flexeril (Cyclobenzaprine) Use in First Trimester

Flexeril should be avoided during the first trimester of pregnancy unless absolutely necessary, as it is classified as FDA Pregnancy Category B with concerning emerging safety signals and no adequate human data to confirm safety.

FDA Classification and Official Guidance

The FDA drug label classifies cyclobenzaprine as Pregnancy Category B 111. While animal reproduction studies at doses up to 20 times the human dose showed no evidence of impaired fertility or fetal harm, there are no adequate and well-controlled studies in pregnant women. The label explicitly states: "Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed" 111.

Emerging Safety Concerns from Human Data

Recent research raises significant red flags that contradict the reassuring animal data:

Birth Defects Association

A large 2023 case-control study combining data from two major U.S. birth defects surveillance systems (33,615 cases, 13,110 controls) found elevated risks for multiple structural birth defects with periconceptional cyclobenzaprine exposure 2:

  • Cleft palate: OR 4.79 (95% CI 1.71-13.44)
  • Anorectal atresia/stenosis: OR 6.91 (95% CI 1.67-28.65)
  • D-transposition of great arteries: OR 6.97 (95% CI 2.17-22.36)
  • Coarctation of aorta: OR 5.58 (95% CI 1.88-16.58)
  • Pulmonary valve stenosis: OR 4.55 (95% CI 1.10-18.87)

While exposure was rare (0.15% of cases, 0.07% of controls) and estimates are unadjusted, the consistency across multiple cardiac and orofacial defects is concerning 2.

Ductal Closure Risk

A 2014 case report documented persistent pulmonary hypertension and early ductal closure in a neonate whose mother used cyclobenzaprine during late pregnancy 3. The proposed mechanism involves cyclobenzaprine's inhibition of norepinephrine and serotonin reuptake, which can suppress prostaglandin and nitric oxide—key factors maintaining ductal patency 3.

Clinical Decision Framework

When cyclobenzaprine is being considered in first trimester:

  1. Assess absolute necessity: Is this for acute muscle spasm that could be managed with safer alternatives?

  2. Consider safer alternatives first:

    • Physical therapy and heat/ice application
    • Acetaminophen for pain relief
    • Short-term NSAIDs (ibuprofen) if before 28 weeks gestation—though data show no teratogenicity risk in first trimester 444
    • Prednisone ≤5 mg/day if inflammatory component (pregnancy-compatible per EULAR guidelines) 44
  3. If cyclobenzaprine exposure has already occurred: Counsel patient about the emerging but imprecise safety signals, offer detailed anatomic ultrasound and fetal echocardiography at 18-22 weeks

  4. Document shared decision-making: If proceeding despite concerns, document discussion of unknown risks, lack of human safety data, and emerging signals

Key Caveats

  • The birth defects study had very small numbers of exposed pregnancies and unadjusted estimates, making causality uncertain 2
  • Cyclobenzaprine is structurally related to tricyclic antidepressants, which have their own pregnancy considerations 11
  • The drug's mechanism (serotonin/norepinephrine reuptake inhibition) theoretically poses risks throughout pregnancy, not just first trimester 3
  • No rheumatology or obstetric guidelines specifically address cyclobenzaprine in pregnancy—the EULAR guidelines focus on disease-modifying drugs and do not mention muscle relaxants 444

Bottom Line

Despite the FDA Category B designation based on animal data, emerging human evidence suggests potential teratogenic risks that warrant extreme caution. The risk-benefit calculation favors avoiding cyclobenzaprine in the first trimester unless no safer alternatives exist for a serious maternal condition. This represents a situation where the FDA label (based on older animal data) may not reflect current understanding from human observational studies.

References

Research

Maternal use of cyclobenzaprine (Flexeril) may induce ductal closure and persistent pulmonary hypertension in neonates.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.